Agilent will showcase the Cary 3500 UV-Vis system at analytica China, being held October 31 November 2, 2018, in Shanghai, China.
Global growth in the development of biological drugs is leading to the evolution of many new biological entities.
Before these NBEs are adapted into therapeutics, laboratories must accurately characterize each new product and continuously monitor the quality of these products throughout the development process.
According to the company, the new system enables laboratories to make substantial gains in efficiency as it can run multiple experiments simultaneously, allowing labs to obtain more results in the same amount of time--and it also extends the opportunity to design experiments in ways that have not been possible before.
The Cary 3500 harnesses the power of a state-of-the-art software platform and a fast and powerful Xenon flash lamp that is redefining UV-Vis spectrophotometry.
Indeed, the system's rapid, accurate, temperature control permits temperature experiments at ramp rates previously thought to be unattainable, providing more reliable and robust measurements.
Agilent Technologies Inc. (NYSE: A) is a leader in life sciences, diagnostics, and applied chemical markets.
With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions.
The company generated revenues of USD 4.47bn in fiscal 2017 and employs 14,500 people worldwide.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development